GA NCORP

TRIALS & PROVIDERS

Menu

NCORP Trials

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Status
Closed
Cancer Type
Unknown Primary
Uterine Cancer
Trial Phase
Phase III
Eligibility
18 Years and older, Female
Study Type
Treatment
NCD ID
NCT03981796
Protocol IDs
213361 (primary)
4010-03-001
NCI-2019-04891
GOG-3031
ENGOT-EN6
Study Sponsor
Tesaro Inc
NCI Full Details
http://clinicaltrials.gov/show/NCT03981796

Summary

This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus
carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel
followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus
carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus
carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced
(Stage III or IV) endometrial cancer.
CALL EMAIL

Copyright © 2015, Georgia NCI Community Oncology Research Program. All Rights Reserved.
Powered by GeorgiaCancerInfo.org
Website Design & Development by Peachtree Solutions.